The sphingosine kinase activator K6PC-5 stimulates C2C12 myoblast differentiation.
Int J Immunopathol Pharmacol
; 24(1): 55-62, 2011.
Article
en En
| MEDLINE
| ID: mdl-21496387
Previously, K6PC-5, a synthetic derivative of ceramide, was demonstrated to activate sphingosine kinase (SK)-1 in keratinocytes. In this study its potential biological effect in mouse myoblasts was examined. The obtained results show that K6PC-5 promotes myogenic differentiation by enhancing myogenic marker expression, differentiation index and fusion index. Interestingly, its biological action was prevented by pharmacological inhibition of SK or S1P2 receptor, in full agreement with their recognized role in myoblast differentiation. This is the first evidence that pharmacological activation of SK accelerates myogenesis and suggests that this new therapeutic strategy could be possibly employed in skeletal muscle disorders where muscle regeneration is deficient.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fosfotransferasas (Aceptor de Grupo Alcohol)
/
Desarrollo de Músculos
/
Mioblastos
/
Amidas
Límite:
Animals
Idioma:
En
Revista:
Int J Immunopathol Pharmacol
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
FARMACOLOGIA
/
PATOLOGIA
Año:
2011
Tipo del documento:
Article
País de afiliación:
Italia
Pais de publicación:
Reino Unido